These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 31862147)

  • 1. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.
    Furler J; O'Neal D; Speight J; Blackberry I; Manski-Nankervis JA; Thuraisingam S; de La Rue K; Ginnivan L; Doyle R; Holmes-Truscott E; Khunti K; Dalziel K; Chiang J; Audehm R; Kennedy M; Clark M; Jenkins A; Lake AJ; Januszewski AS; Catchpool M; Liew D; Clarke P; Best J
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):17-26. PubMed ID: 31862147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP-OSMOTIC trial protocol: an individually randomised controlled trial to determine the effect of retrospective continuous glucose monitoring (r-CGM) on HbA1c in adults with type 2 diabetes in general practice.
    Furler J; O'Neal DN; Speight J; Blackberry I; Manski-Nankervis JA; Thuraisingam S; de La Rue K; Ginnivan L; Browne JL; Holmes-Truscott E; Khunti K; Dalziel K; Chiang J; Audehm R; Kennedy M; Clark M; Jenkins AJ; Liew D; Clarke P; Best J
    BMJ Open; 2018 Jul; 8(7):e021435. PubMed ID: 30018097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of professional-mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GP-OSMOTIC trial.
    Hua X; Catchpool M; Clarke P; Blackberry I; Chiang J; Holmes-Truscott E; Jenkins A; Khunti K; O'Neal D; Speight J; Furler J; Manski-Nankervis JA; Dalziel K;
    Diabet Med; 2022 Mar; 39(3):e14747. PubMed ID: 34806780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.
    van Beers CA; DeVries JH; Kleijer SJ; Smits MM; Geelhoed-Duijvestijn PH; Kramer MH; Diamant M; Snoek FJ; Serné EH
    Lancet Diabetes Endocrinol; 2016 Nov; 4(11):893-902. PubMed ID: 27641781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Socioeconomic status and time in glucose target range in people with type 2 diabetes: a baseline analysis of the GP-OSMOTIC study.
    Tan ML; Manski-Nankervis JA; Thuraisingam S; Jenkins A; O'Neal D; Furler J
    BMC Endocr Disord; 2018 Jul; 18(1):47. PubMed ID: 30031385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of 6 months' flash glucose monitoring in adolescents and young adults with type 1 diabetes and suboptimal glycaemic control: managing diabetes in a 'flash' randomised controlled trial protocol.
    Boucher SE; Gray AR; de Bock M; Wiltshire EJ; Galland BC; Tomlinson PA; Rayns J; MacKenzie KE; Wheeler BJ
    BMC Endocr Disord; 2019 May; 19(1):50. PubMed ID: 31109342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial.
    Visser MM; Charleer S; Fieuws S; De Block C; Hilbrands R; Van Huffel L; Maes T; Vanhaverbeke G; Dirinck E; Myngheer N; Vercammen C; Nobels F; Keymeulen B; Mathieu C; Gillard P
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):96-108. PubMed ID: 36702566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of quarterly professional-mode flash glucose monitoring in adults with type 2 diabetes in general practice (GP-OSMOTIC): Secondary psychological and self-care outcomes of a pragmatic, open-label, 12-month, randomised controlled trial.
    Speight J; Holmes-Truscott E; Thuraisingam S; Mohamad Husin H; Manski-Nankervis JA; De La Rue K; Ginnivan L; Audehm R; Clark M; Khunti K; O'Neal D; Furler J;
    Diabetes Res Clin Pract; 2021 Sep; 179():108994. PubMed ID: 34363864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
    Heinemann L; Freckmann G; Ehrmann D; Faber-Heinemann G; Guerra S; Waldenmaier D; Hermanns N
    Lancet; 2018 Apr; 391(10128):1367-1377. PubMed ID: 29459019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial.
    Haak T; Hanaire H; Ajjan R; Hermanns N; Riveline JP; Rayman G
    Diabetes Ther; 2017 Feb; 8(1):55-73. PubMed ID: 28000140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial.
    Bolinder J; Antuna R; Geelhoed-Duijvestijn P; Kröger J; Weitgasser R
    Lancet; 2016 Nov; 388(10057):2254-2263. PubMed ID: 27634581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial.
    Kim JY; Jin SM; Sim KH; Kim BY; Cho JH; Moon JS; Lim S; Kang ES; Park CY; Kim SG; Kim JH
    Diabetologia; 2024 Jul; 67(7):1223-1234. PubMed ID: 38639876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non-insulin treated Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial.
    Parsons SN; Luzio SD; Harvey JN; Bain SC; Cheung WY; Watkins A; Owens DR
    Diabet Med; 2019 May; 36(5):578-590. PubMed ID: 30653704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial.
    Furler J; O'Neal D; Speight J; Manski-Nankervis JA; Gorelik A; Holmes-Truscott E; Ginnivan L; Young D; Best J; ; Patterson E; Liew D; Segal L; May C; Blackberry I
    BMJ; 2017 Mar; 356():j783. PubMed ID: 28274941
    [No Abstract]   [Full Text] [Related]  

  • 19. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study.
    Leelarathna L; Sutton CJ; Evans ML; Neupane S; Rayman G; Lumley S; Cranston I; Narendran P; Krishan A; Taxiarchi VP; Barnard-Kelly K; Elliott RA; Burns M; Camm M; Thabit H; Wilmot EG;
    Diabet Med; 2024 Mar; 41(3):e15249. PubMed ID: 37897112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.